<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS190788</article-id><article-id pub-id-type="doi">10.1101/2023.11.06.565756</article-id><article-id pub-id-type="archive">PPR754138</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A single-cell multi-omic and spatial atlas of B-cell lymphomas reveals differentiation drives intratumor heterogeneity: Differentiation drives variation in B-cell lymphomas</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fitzgerald</surname><given-names>Donnacha</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Roider</surname><given-names>Tobias</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Baertsch</surname><given-names>Marc-Andrea</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kibler</surname><given-names>Artur</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Horlova</surname><given-names>Anastasiia</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Erin</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Vöhringer</surname><given-names>Harald</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mathioudaki</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Budeus</surname><given-names>Bettina</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Passerini</surname><given-names>Verena</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Knoll</surname><given-names>Mareike</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mammen</surname><given-names>Johannes</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Linsha</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Caillé</surname><given-names>Léandra</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Czernilofsky</surname><given-names>Felix</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bruch</surname><given-names>Peter-Martin</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Liebers</surname><given-names>Nora</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A10">10</xref><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Meyer-Bender</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Siebert</surname><given-names>Reiner</given-names></name><xref ref-type="aff" rid="A12">12</xref></contrib><contrib contrib-type="author"><name><surname>Weigert</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="A9">9</xref><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Zaugg</surname><given-names>Judith</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Nolan</surname><given-names>Garry</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Seifert</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Dietrich</surname><given-names>Sascha</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A10">10</xref><xref ref-type="fn" rid="FN1">13</xref><xref ref-type="corresp" rid="CR1">14</xref></contrib><contrib contrib-type="author"><name><surname>Huber</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="fn" rid="FN1">13</xref><xref ref-type="corresp" rid="CR1">14</xref></contrib></contrib-group><aff id="A1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03mstc592</institution-id><institution>European Molecular Biology Laboratory (EMBL)</institution></institution-wrap>, Molecular Medicine Partnership Unit (MMPU), <city>Heidelberg</city>, <country country="DE">Germany</country></aff><aff id="A2"><label>2</label>Department of Hematology, Oncology and Rheumatology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013czdx64</institution-id><institution>Heidelberg University Hospital</institution></institution-wrap>, <city>Heidelberg</city>, <country country="DE">Germany</country></aff><aff id="A3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03mstc592</institution-id><institution>European Molecular Biology Laboratory (EMBL)</institution></institution-wrap>, Genome Biology Unit, <city>Heidelberg</city>, <country country="DE">Germany</country></aff><aff id="A4"><label>4</label>School of Medicine, Department of Microbiology and Immunology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University</institution></institution-wrap>, <city>Stanford</city>, <state>CA</state>, <country country="US">USA</country></aff><aff id="A5"><label>5</label>Department of Oncology, Hematology and Clinical Immunology, Medical Faculty of Heinrich-Heine-Universität, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/006k2kk72</institution-id><institution>Düsseldorf University Hospital</institution></institution-wrap>, <city>Düsseldorf</city>, <country country="DE">Germany</country></aff><aff id="A6"><label>6</label>Institute of Cell Biology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04mz5ra38</institution-id><institution>University of Duisburg-Essen</institution></institution-wrap>, <city>Essen</city>, <country country="DE">Germany</country></aff><aff id="A7"><label>7</label>Department of Molecular Genetics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02na8dn90</institution-id><institution>Essen University Hospital</institution></institution-wrap>, <city>Essen</city>, <country country="DE">Germany</country></aff><aff id="A8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03mstc592</institution-id><institution>European Molecular Biology Laboratory (EMBL)</institution></institution-wrap>, Structural and Computational Biology Unit, <city>Heidelberg</city>, <country country="DE">Germany</country></aff><aff id="A9"><label>9</label>Medical Department III, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany</aff><aff id="A10"><label>10</label>Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany</aff><aff id="A11"><label>11</label>Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cdgtt98</institution-id><institution>German Cancer Research Center (DKFZ)</institution></institution-wrap>, <city>Heidelberg</city>, <country country="DE">Germany</country></aff><aff id="A12"><label>12</label>Institute of Human Genetics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/032000t02</institution-id><institution>Ulm University</institution></institution-wrap>, <city>Ulm</city>, <country country="DE">Germany</country></aff><author-notes><corresp id="CR1">
<label>14</label>Correspondence: <email>wolfgang.huber@embl.org</email>, <email>sascha.dietrich@embl.de</email></corresp><fn id="FN1" fn-type="equal"><label>13</label><p id="P1">These senior authors contributed equally to this study</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>09</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>07</day><month>11</month><year>2023</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">CC BY-NC 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P2">Intratumor heterogeneity underpins cancer pathogenesis and evolution, although it is typically considered independent from the differentiation processes that drive physiological cell-type diversity. As cancer types and subtypes arise from different cell types, we investigated whether cellular differentiation influences intratumor heterogeneity. Nodal B-cell non-Hodgkin lymphomas are a diverse set of cancers originating from different stages of B-cell maturation. Through single-cell transcriptome and surface epitope profiling (CITE-Seq) of diffuse large B-cell, mantle cell, follicular, and marginal zone lymphomas in addition to reactive lymph nodes from 51 patients, we found multiple B-cell maturation states within tumors. Intratumor maturation states emerged from the same clone, revealing divergent differentiation from a shared cell of origin. Maturation state composition varied across subtypes and tumors, which encompassed mixed cell-of-origin diagnostic subtypes. Through highly multiplexed immunohistochemistry (CODEX) of samples from 19 of these patients, we found that intratumor maturation states inhabited distinct spatial niches, displaying cellular interactions and regulatory networks typical of their maturation states while harboring different genetic variants. By deconvoluting intratumor maturation states from a microarray dataset of 507 patients, we identified risk groups within diagnoses with striking differences in survival, including IgM memory-enriched germinal center B-cell (M = 1.9 vs &gt;10 years, p = 0.00039) and activated B-cell (M = 2.4 vs 9.6 years, p = 0.016) diffuse large B-cell lymphoma, and dark zone-enriched follicular lymphoma (M = 8.6 vs 13 years; p = 0.0019). Our findings reveal cellular differentiation remains plastic in B-cell lymphomas, driving tumor variation, evolution, and response.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P3">Cellular differentiation gives rise to the diversity of cell types and states observed across organs, tissues, and developmental lineages. Distinct cancer types and subtypes can emerge from these. The cell of origin, defined as the cell that acquired the first genetic aberrations that then lead to cancer, is widely thought to be a major determinant of tumor behavior and response to therapy<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. The molecular and functional features inherited by tumor cells from their cell of origin have clinical relevance for many cancer types<sup><xref ref-type="bibr" rid="R2">2</xref></sup>.</p><p id="P4">B-cell lymphomas, a heterogeneous set of malignancies arising from different stages of B-cell maturation in lymph nodes, have been well studied in this regard. In the B-cell maturation process, naïve B cells enter the germinal center (GC) upon T-cell dependent activation, where they proliferate and undergo somatic hypermutation in the dark zone (DZ) before migrating to the light zone (LZ) for antigen presentation by T follicular helper cells (TFH) and follicular dendritic cells (FDC), leading to differentiation into memory B cells (Mem) or plasma cells<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref></sup>. B-cell lymphoma subtypes include typically pre-GC mantle cell lymphoma (MCL), GC diffuse large B-cell lymphoma (DLBCL, GCB) and follicular lymphoma (FL), post-GC or activated B-cell DLBCL (DLBCL, non-GCB/ABC), as well as memory-origin marginal zone lymphoma (MZL)<sup><xref ref-type="bibr" rid="R4">4</xref>–<xref ref-type="bibr" rid="R7">7</xref></sup>. These B-cell lymphoma subtypes have variable clinical courses, ranging from the more indolent FL and MZL to the more aggressive MCL and DLBCL<sup><xref ref-type="bibr" rid="R8">8</xref></sup>. Following standard treatment with chemoimmunotherapy, ABC-like-DLBCL shows more frequent relapse compared to GCB-like-DLBCL. This association between DLBCL tumor maturation state and clinical outcomes has more recently been extended beyond the ABC vs GCB dichotomy to across the maturation spectrum<sup><xref ref-type="bibr" rid="R9">9</xref></sup>.</p><p id="P5">In addition to the cell of origin, cancer pathogenesis and treatment response are also shaped by intratumor heterogeneity<sup><xref ref-type="bibr" rid="R13">13</xref></sup>. Intratumor heterogeneity can manifest at genetic, epigenetic, cellular phenotype, and microenvironment levels, contributing to complex tumor architecture, evolution, and adaptive resistance mechanisms<sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R14">14</xref></sup>. Greater intratumor heterogeneity has been associated with a worse prognosis, due to the increased likelihood of therapy-resistant subclones<sup><xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R17">17</xref></sup>. In B-cell lymphoma, substantial heterogeneity has been observed in the tumor microenvironment, including in stromal<sup><xref ref-type="bibr" rid="R18">18</xref></sup> and T-cell infiltration patterns<sup><xref ref-type="bibr" rid="R19">19</xref></sup>, while intratumor transcriptional subpopulations have shown differences in their treatment sensitivities<sup><xref ref-type="bibr" rid="R10">10</xref></sup>.</p><p id="P6">Understanding the drivers of intratumor heterogeneity promises to improve our understanding of cancer pathogenesis, evolution, and resistance mechanisms. While cell of origin significantly contributes to <italic>inter</italic>tumor heterogeneity, the role of differentiation processes like B-cell maturation in <italic>intra</italic>tumor heterogeneity is unclear. Dedifferentiation into cancer stem cells and transdifferentiation across lineages have been recognized in several other cancer types<sup><xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R21">21</xref></sup>, and limited plasticity beyond the cell of origin has been noted in 4 FL<sup><xref ref-type="bibr" rid="R22">22</xref></sup> and 4 DLBCL<sup><xref ref-type="bibr" rid="R23">23</xref></sup> tumors. Nevertheless, the prevailing paradigm in cancer pathogenesis remains that cancer cells avert normal cellular differentiation to avoid terminal differentiation and maintain proliferation<sup><xref ref-type="bibr" rid="R24">24</xref>–<xref ref-type="bibr" rid="R26">26</xref></sup>. Through transcriptional, proteomic, epigenetic, genetic, and spatial profiling of MCL, FL, DLBCL, MZL, and reactive lymph nodes (rLN) across 51 patients, representing the largest cross-entity single-cell atlas of B-cell lymphoma tumors to date, we show that cellular differentiation continues in malignancy, driving intratumor heterogeneity and response.</p></sec><sec id="S2" sec-type="methods"><title>Methods</title><sec id="S3"><title>Study outline</title><p id="P7">This study was approved by the University of Heidelberg’s Ethics Committee (S-254/2016), with informed consent obtained from all participants. Lymph node (LN) samples from 51 patients (8 MCL; 12 FL; 5 GCB DLBCL; 7 ABC DLBCL; 11 MZL; 8 rLN, <xref ref-type="supplementary-material" rid="SD1">Supplemental Table 1</xref>) were processed and cryopreserved using published protocols<sup><xref ref-type="bibr" rid="R27">27</xref></sup>. Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-Seq)<sup><xref ref-type="bibr" rid="R28">28</xref></sup> and Chromium Single Cell Immune Profiling were performed as per the manufacturer’s (10X Genomics) instructions and analyzed with the <italic>Seurat</italic><sup><xref ref-type="bibr" rid="R29">29</xref></sup> R package. Highly multiplexed histochemistry (CODEX) was performed as previously described<sup><xref ref-type="bibr" rid="R30">30</xref></sup>. Antibody panels are outlined in <xref ref-type="supplementary-material" rid="SD1">Supplemental Tables 2-4</xref>. Transcription factor activity and copy number variants were inferred with the <italic>SCENIC</italic><sup><xref ref-type="bibr" rid="R31">31</xref></sup> and <italic>copykat</italic><sup><xref ref-type="bibr" rid="R32">32</xref></sup> packages. Targeted DNA sequencing was performed on the targets outlined in <xref ref-type="supplementary-material" rid="SD3">Supplemental Table 7</xref>. Gene set enrichment analysis was performed with the <italic>fgsea</italic><sup><xref ref-type="bibr" rid="R33">33</xref></sup> R package using the MSigDB hallmark gene set collection<sup><xref ref-type="bibr" rid="R34">34</xref></sup>. For survival analysis, the maturation state composition of 507 FL and DLBCL tumors was deconvoluted from the Loeffler-Wirth et al. 2019<sup><xref ref-type="bibr" rid="R35">35</xref></sup> microarray dataset using CIBERSORTx<sup><xref ref-type="bibr" rid="R36">36</xref></sup>. Cox proportional hazards models and Kaplan-Meier curves were generated with the <italic>survival</italic><sup><xref ref-type="bibr" rid="R37">37</xref></sup> and <italic>survminer</italic><sup><xref ref-type="bibr" rid="R38">38</xref></sup> R packages. See the Extended Methods section of the Supplemental Data for a more detailed description of the methods.</p></sec></sec><sec id="S4" sec-type="results"><title>Results</title><sec id="S5"><title>A single-cell B-cell maturation reference map in reactive lymph nodes</title><p id="P8">To characterize nodal B-cell maturation states in the non-malignant context, we performed Louvain clustering on the rLN single-cell transcriptomic data, obtaining 16 clusters that we assigned to naïve, germinal dark zone centroblasts (DZ), light zone centrocytes (LZ), IgD+/IgM+ memory (Mem IgM), class-switched memory of predominantly IgG class (Mem IgG), and plasma maturation states based on the presence of established markers<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R43">43</xref></sup>(<xref ref-type="supplementary-material" rid="SD1">Supplemental Table 5</xref>, <xref ref-type="fig" rid="F1">Fig. 1b-c</xref>). These B-cell maturation state annotations were validated with FACS sorting and RNA sequencing, which confirmed the presence and gene expression profiles of the identified states (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 1</xref>, <xref ref-type="fig" rid="F1">Fig. 1d</xref>). We observed that the rLN samples were composed of 60% memory (split equally between IgD+/IgM+ (Mem IgM), and class-switched (Mem IgG)), 30% naïve, 6% light zone centrocytes (LZ), 3% dark zone centroblasts (DZ), and 2% plasma cells.</p></sec><sec id="S6"><title>Divergence of B-cell maturation in tumors</title><p id="P9">Having characterized B-cell maturation states in non-malignant lymph nodes, we profiled these states in the 43 B-cell lymphoma samples (8 MCL, 12 FL, 5 GCB DLBCL, 7 non-GCB DLBCL, and 11 MZL). We identified malignant cells based on light chain restriction<sup><xref ref-type="bibr" rid="R44">44</xref></sup>, with transcriptional clusters having &gt;75% kappa or lambda light chains considered malignant.</p><p id="P10">BCR profiling in 8 samples confirmed each tumor had a single expanded B-cell receptor clone with a restricted light chain. Non-malignant B cells, mainly naïve B cells, comprised a median of 6% [0%-94%] of all B cells across tumor samples (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 2</xref>).</p><p id="P11">To classify B-cell maturation states in tumors, we used mutual nearest neighbors and canonical correlation analysis<sup><xref ref-type="bibr" rid="R45">45</xref></sup> to map maturation states from the rLN reference dataset to each tumor. The classified maturation states in malignant cells matched their maturation marker profiles. We also calculated maturation state gene signature scores using the 50 most differentially expressed genes from a published tonsil dataset<sup><xref ref-type="bibr" rid="R9">9</xref></sup>, and these scores in tumors reflected those in rLN samples (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 3a-b</xref>).</p><p id="P12">Hereon focusing on malignant B cells, we found that tumors displayed a spectrum of maturation states, indicating plasticity and divergence from a common cell of origin (<xref ref-type="fig" rid="F2">Fig. 2a-b</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 4</xref>). This indicates that B-cell maturation remains plastic and divergent in malignancy, rather than fixed.</p></sec><sec id="S7"><title>Maturation states are a source of intratumor and intertumor heterogeneity</title><p id="P13">We observed a characteristic spectrum of maturation states in each subtype; the predominant states reflected their associated cell of origin, such as GC states in DLBCL GCB and memory states in MZL, and co-existed with states both upstream and downstream in the maturation process. We also observed substantial variation in maturation state proportions between samples of the same subtype (<xref ref-type="fig" rid="F2">Fig. 2b</xref>). B-cell maturation states contributed significantly to both intratumor and intertumor heterogeneity, with subtype prediction accuracy reflecting this complexity (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 3c</xref>).</p><p id="P14">FL and non-GCB DLBCL tumors showed diverse mixtures of GC (DZ and LZ) and post-GC (memory and plasma) states, suggesting that, like DLBCL, FL may also be capable of transformation into post-GC phenotypes. Both DLBCL and FL showed significant enrichment in the LZ state compared to rLN controls (p &lt; 0.01, Wilcoxon signed rank test), but FL tumors were not enriched for the DZ state (<xref ref-type="fig" rid="F2">Fig. 2b</xref>), implying that DLBCL better maintains a DZ phenotype. Continuation of somatic hypermutation and proliferation in the DZ state may promote DLBCL’s characteristically more aggressive disease course<sup><xref ref-type="bibr" rid="R46">46</xref></sup>.</p><p id="P15">We explored phenotypic diversity in B-cell lymphoma tumor cells by conducting unsupervised multimodal subpopulation mapping on the full CITE-Seq B-cell dataset (51 samples, 154,282 cells). Using Multi-Omic Factor Analysis (MOFA)<sup><xref ref-type="bibr" rid="R47">47</xref></sup>, we identified 26 multimodal subpopulations, mostly segregating by maturation state, underscoring differentiation as a major driver of tumor variation (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 5a-e</xref>). The greatest heterogeneity was observed among memory B-cell states, with subpopulations segregating by B-cell lymphoma subtype. Features of these subpopulations pointed to known pathogenic mechanisms, such as CCND1 overexpression in MCL<sup><xref ref-type="bibr" rid="R48">48</xref></sup> (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 5f-g</xref>).</p></sec><sec id="S8"><title>Cell-of-origin classification reveals multiple subtypes within each tumor</title><p id="P16">Next, we examined the implications of intratumor variation in maturation states for established diagnostic cell-of-origin (COO) classifiers. Applying the Lymph2Cx gene expression classifier<sup><xref ref-type="bibr" rid="R49">49</xref></sup> to single-cell RNA-sequencing (scRNA-seq) data from DLBCL tumors revealed that most tumors consisted of multiple COO subtypes (GCB, unclassified, and ABC), rather than a single GCB or ABC class per tumor. This indicates a more complex pathology in DLBCL, with a mixture of COO subtypes within each tumor (<xref ref-type="fig" rid="F3">Fig. 3a-b</xref>). This observation was confirmed using the Tally DLBCL COO classifier, which employs immunohistochemistry markers (e.g., CD10, GCET1, LMO2 for GCB; MUM1, FOXP1 for non-GCB) to classify tumors<sup><xref ref-type="bibr" rid="R50">50</xref></sup>. Both classifiers showed that GCB DLBCL often contains ABC-like cells, consistent with a portion of GCB-origin tumor cells transitioning to an ABC subtype (<xref ref-type="fig" rid="F3">Fig. 3d-e</xref>).</p><p id="P17">Interestingly, FL tumors, typically not associated with an ABC cell of origin, displayed both GCB and ABC classes at the single-cell level in 10 out of 12 tumors when using Lymph2Cx and Tally classifiers. This suggests the emergence of an ABC-like population within FL tumors (<xref ref-type="fig" rid="F3">Fig. 3c+f</xref>).</p></sec><sec id="S9"><title>Tumor maturation state composition changes over time</title><p id="P18">We hypothesized that intratumor heterogeneity introduced by B-cell maturation might drive tumor evolution, with shifts in maturation state composition over time due to disease progression or treatment selection. This hypothesis was supported by observed increases in class-switched memory (Mem IgG) and plasma states in MZL and an increase in the ABC COO subtype in FL samples collected later in the disease course (<xref ref-type="fig" rid="F2">Fig. 2b</xref>). In longitudinal lymph node samples from three B-cell lymphoma patients, we observed shifts in maturation state composition, such as a decrease in plasma cells and an increase in Mem IgG in an MZL tumor that relapsed 15 months after 6 cycles of obinutuzumab and bendamustine (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 6a</xref>). Similarly, plasma cells increased after 11 months in a GCB DLBCL tumor that relapsed following CAR-T therapy (axicabtagene ciloleucel) (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 6b</xref>). However, little change was observed after 2 months in another DLBCL patient who relapsed to the same CAR-T therapy, suggesting that these effects may be time-dependent (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 6c</xref>).</p></sec><sec id="S10"><title>Transcription factor signatures of maturation states maintain differential activity in malignancy</title><p id="P19">Transcription factors (TFs) are key mediators of the B-cell maturation process, although alteration of the epigenomic landscape has been described in the pathogenesis of B-cell lymphoma<sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R39">39</xref>,<xref ref-type="bibr" rid="R51">51</xref>–<xref ref-type="bibr" rid="R53">53</xref></sup>. We investigated whether maturation-associated TFs were maintained in malignancy, which could enable a tumor to diverge into multiple maturation states despite epigenomic dysregulation. Using the <italic>SCENIC</italic> workflow<sup><xref ref-type="bibr" rid="R31">31</xref></sup> on scRNA-seq data (51 samples), we identified coexpression modules between TFs and target genes, scoring TF activity based on module expression. Signature TFs were defined by differentially expressed target genes between maturation states in rLN samples (BH-adjusted p-value &lt; 10e-16, average log fold-change &gt; 0.4). These maturation TF signatures were largely conserved across B-cell lymphoma subtypes, though this conservation was partially lost in the LZ state of DLBCL, where TFs like <italic>IRF8, NFKB1, HIVEP3</italic>, and <italic>REL</italic>, elevated in rLN LZ, showed higher activity in the memory state (<xref ref-type="fig" rid="F4">Fig. 4a</xref>). Variation in memory signature TF activity across subtypes (e.g., <italic>IRF7, STAT1, IRF9</italic>) corresponded with the diversity of nodal memory B-cells, which are less dependent on maturation GRNs after completing the maturation process. TFs with the most significant activity differences in malignancy were linked to B-cell development, activation, and differentiation, including <italic>KLF3</italic> in naïve and memory B cells, <italic>MAZ</italic> and <italic>HDAC2</italic> in GC B cells, <italic>TBL1XR1</italic> in memory, and <italic>XBP1</italic> in plasma cells (<xref ref-type="fig" rid="F4">Fig. 4b</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 7</xref>).</p></sec><sec id="S11"><title>Maturation states occupy distinct tumor microenvironments</title><p id="P20">The follicular architecture of lymph nodes is central to the B-cell maturation process. Therefore, we sought to understand the spatial context of intratumor maturation states and whether spatial niches could still facilitate maturation in malignancy. We characterized the spatial distribution of cell types with CODEX<sup><xref ref-type="bibr" rid="R30">30</xref></sup> (52 features, <xref ref-type="supplementary-material" rid="SD3">Supplemental Table 7</xref>) for 19 samples (29 slides) in the CITE-Seq cohort. Immune cell types were defined according to previously published nodal cell type annotations<sup><xref ref-type="bibr" rid="R19">19</xref></sup> (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 9a</xref>). B-cell maturation state labels were transferred from the CITE-Seq to the CODEX dataset via shared protein features (n=28), yielding a high correlation in maturation state proportions between the datasets across samples (median R=0.91, p=0.011) (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 8</xref>). Tumor microenvironment composition varied significantly across tumors and subtypes, with MCL and DLBCL typically losing normal follicular structure. However, tumor cells of different maturation states still tended to segregate spatially (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 9b</xref>). For instance, FL1 showed expanded follicles with DZ and LZ states surrounded by memory and plasma cells. At the same time, MCL1 exhibited spatially distinct LZ and memory states, but without typical follicular structure. ABC2 displayed a spread of several maturation states with little spatial distinction, consistent with DLBCL’s diffuse nature (<xref ref-type="fig" rid="F5">Fig. 5a</xref>).</p><p id="P21">We explored spatial niches using K nearest neighbor (KNN, K = 20) graph-based cellular neighborhood (CN) analysis, identifying 11 CNs defined by enriched cell types (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 10</xref>). CNs common in rLNs were also present in tumors, including T-cell zones and a stromal zone bordering B cells. However, most malignant B cells were found in CNs distinct from the follicular CNs seen in rLN samples. Each intratumor maturation state was dominant in a different CN and associated with different immune compositions, such as cytotoxic T-cells and macrophages in plasma zones (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 10</xref>).</p><p id="P22">Heterogeneous microenvironments may promote maturation state divergence by enabling or restricting specific cellular interactions critical to maturation. FDCs and TFH cells were enriched in GC-predominant tumor CNs, potentially supporting the ongoing differentiation of malignant GC cells into post-GC memory or plasma cells (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 10b</xref>). Pairwise cell-cell interaction ratios (IR) between B-cell maturation states and other cell types indicated that GC B-cell interactions with FDC and TFH were partially maintained in tumors, allowing the GC reaction to continue in malignancy. This was less evident in the more diffuse DLBCL and generally post-GC MZL, possibly explaining their lower diversity of maturation states compared to FL (<xref ref-type="fig" rid="F2">Fig. 2b</xref>).</p></sec><sec id="S12"><title>Genetic variants among intratumor maturation states</title><p id="P23">Several characteristic features of B-cell maturation states are known to be commonly aberrated in B-cell lymphoma (eg. <italic>BCL6, IRF4,</italic> and <italic>PRDM1</italic>)<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R54">54</xref></sup>. We considered whether intratumor maturation states may be associated with subclonal genetic variation. We profiled genetic variants, including single-nucleotide variants (SNVs), insertions and deletions, and copy number variants (CNVs) from targeted DNA-sequencing data in bulk tumor samples. We inferred CNVs at the single-cell level from gene expression data using the <italic>copykat</italic> method<sup><xref ref-type="bibr" rid="R32">32</xref></sup>. Distinct CNVs were observed within individual tumors, often confined to specific maturation states. For example, in FL7, most GC tumor cells displayed aneuploidy compared to predominantly diploid non-GC cells (<xref ref-type="fig" rid="F6">Fig. 6a-d</xref>). This tumor exhibited a 6p22.2 copy number gain, associated with FL progression<sup><xref ref-type="bibr" rid="R55">55</xref></sup>, restricted to DZ tumor cells (<xref ref-type="fig" rid="F6">Fig. 6c</xref>), suggesting that this gain may either lock cells in the DZ stage or that DZ cells are more prone to acquiring such variants.</p><p id="P24">Genes harboring non-silent mutations also differed in expression between intratumor maturation states. For instance, an MCL tumor with multi-hit <italic>ATM</italic> mutations showed restored expression in post-GC states, while an FL tumor with <italic>HIST1H1E</italic> and <italic>DTX1</italic> mutations showed reduced expression in post-DZ states (<xref ref-type="fig" rid="F6">Fig. 6e</xref>). These findings are consistent with a recent study in which we observed differential mutation abundance between maturation states in the same tumor (eg. BCL2 variants enriched in LZ vs DZ)<sup><xref ref-type="bibr" rid="R56">56</xref></sup>.</p></sec><sec id="S13"><title>Tumor maturation state composition predicts survival</title><p id="P25">We investigated the impact of intratumor B-cell maturation state heterogeneity on survival by deconvoluting maturation states with CIBERSORTx<sup><xref ref-type="bibr" rid="R36">36</xref></sup> from a microarray dataset containing 430 DLBCL, 145 FL, and 48 mixed FL/DLBCL tumors that were heterogeneously treated pre-Rituximab era<sup><xref ref-type="bibr" rid="R35">35</xref></sup>. Cox proportional hazards analysis revealed that IgM memory and DZ states were associated with poorer survival, while LZ and naïve states were linked to prolonged survival (<xref ref-type="fig" rid="F7">Fig. 7a</xref>). Gene set enrichment analysis showed that IgM memory and DZ states exhibited increased proliferation and cell growth (Myc, E2F, and mTOR) signaling and DNA repair, indicative of a more aggressive and resistant phenotype<sup><xref ref-type="bibr" rid="R57">57</xref>,<xref ref-type="bibr" rid="R58">58</xref></sup> (<xref ref-type="fig" rid="F7">Fig. 7b-c</xref>). The DZ state showed reduced dependence on canonical TNF, JAK-STAT, and KRAS signaling compared to other tumor populations, which could enable them to escape the typical immune response and therapeutic interventions (<xref ref-type="fig" rid="F7">Fig. 7b-c</xref>). IgM memory B cells can class switch to IgG/IgA memory, differentiate into plasma cells, or re-enter the germinal center reaction to undergo further somatic hypermutation and proliferation<sup><xref ref-type="bibr" rid="R59">59</xref></sup>. This special plasticity could give IgM memory tumor cells an evolutionary advantage through adaptation, thus driving poorer survival outcomes.</p><p id="P26">We identified distinct survival groups based on maturation state proportions. In FL, tumors enriched for DZ cells showed a more aggressive course (median survival = 8.6 vs. 13 years; χ<sup>2</sup> = 9.6, df = 1, p = 0.0019). In DLBCL, IgM memory high and low subgroups had striking survival differences in both GCB and ABC subtypes (GCB: median = 1.9 vs. &gt;10 years, χ<sup>2</sup> = 12.6, df = 1, p = 0.00039; ABC: median = 2.4 vs. 9.6 years, χ<sup>2</sup> = 5.8, df = 1, p = 0.016). These results suggest that intratumor maturation state profiling can identify high-risk patient groups within B-cell lymphoma subtypes.</p></sec></sec><sec id="S14" sec-type="discussion"><title>Discussion</title><p id="P27">The prevailing view in cancer pathogenesis is that normal cellular differentiation is averted in malignancy, while cancer types and subtypes are tied to distinct cell types and states<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R54">54</xref></sup>.</p><p id="P28">In this paradigm, B-cell lymphoma subtypes are associated with different stages of the B-cell maturation lineage<sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R54">54</xref></sup>. In contrast, our study reveals that ongoing differentiation drives intratumor heterogeneity in MCL, FL, DLBCL, and MZL, with tumors exhibiting a spectrum of B-cell maturation states.</p><p id="P29">We show that ongoing B-cell maturation is a major driver of intratumor heterogeneity across B-cell lymphoma subtypes. Intratumor heterogeneity in maturation states transcends subtype boundaries, which are tied to different cell types of origin. This deviation in maturation is bidirectional; post-GC states are observed in GC tumors (eg., FL), and GC states are observed in post-GC tumors (eg., DLBCL non-GCB and MZL). This raises two potential roles of maturation in B-cell lymphoma pathogenesis; it may either enable additional tumor maturation states to evolve from the subtype-determining cell of origin or drive the emergence of the predominant subtype-associated tumor maturation state from a cell of origin earlier in the maturation process.</p><p id="P30">As B-cell lymphoma subtypes<sup><xref ref-type="bibr" rid="R8">8</xref></sup> associated with different maturation states (e.g. GCB vs ABC in DLBCL)<sup><xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R60">60</xref></sup> have distinct clinical outcomes, variation in tumor maturation state composition may explain the variable disease courses among patients. This is especially plausible given that the Lymph2Cx and Tally DLBCL cell-of-origin subtype classifiers, which distinguish GCB and ABC DLBCL subtypes with distinct prognoses, reveal the presence of both GCB and ABC classes within individual tumors, even in FL where a post-GC subtype has not yet been described. Thus, intratumor heterogeneity in maturation may require revising B-cell lymphoma subtypes to account for mutability and multiplicity of maturation states within tumors. The identification of survival-based subgroups of FL, GCB DLBCL and ABC DLBCL based on the abundance of DZ and IgM memory states suggests that tumor maturation state profiling could be used for patient stratification and management. Future studies may link this intratumor heterogeneity to evolving molecular classifications of B-cell lymphomas (e.g., DZsig<sup><xref ref-type="bibr" rid="R61">61</xref></sup> and LymphGen<sup><xref ref-type="bibr" rid="R62">62</xref></sup>) and study cancer cell type diversity and its consequences across cancers.</p><p id="P31">The plasticity in B-cell maturation observed in malignancy would enable shifts in intratumor maturation states over time, promoting tumor evolution and expanding the selection pool for treatment resistance. Understanding the link between intratumor maturation states and resistance mechanisms could inform treatment stratification strategies. Targeting vulnerabilities in specific maturation states, or blocking differentiation to more resistant states, could offer therapeutic opportunities. Some pathways and gene regulatory networks (e.g., XBP1, HDAC2<sup><xref ref-type="bibr" rid="R63">63</xref></sup>) already have known ligands or approved drugs, though care is needed to avoid immunosuppression.</p><p id="P32">The tumor microenvironment plays a fundamental role in B-cell lymphoma pathogenesis, largely by influencing survival and growth signalings and immune infiltration or blockade<sup><xref ref-type="bibr" rid="R64">64</xref></sup>. While disruption of follicular structures has long been recognized in B-cell lymphomas<sup><xref ref-type="bibr" rid="R65">65</xref></sup>, the spatial segregation of maturation states within tumors—such as FDC and TFH co-localizing with GC tumor states—may explain how different maturation states can differentiate within a tumor. The greater diversity of maturation states in FL compared to GCB DLBCL suggests that retention of follicular structures may better preserve the maturation process. With the success of CAR-T and bi-specific T-cell engagers (BiTEs) in relapsed or refractory DLBCL<sup><xref ref-type="bibr" rid="R66">66</xref>,<xref ref-type="bibr" rid="R67">67</xref></sup>, varying patterns of T-cell interactions across intratumor maturation states raise the question of whether immunotherapy should be tailored to the tumor’s maturation state composition, potentially requiring combination approaches to account for multiple spatial niches. Additionally, the diverse microenvironments around tumor maturation states encourage research into expanding the immunotherapy repertoire, including myeloid cells and non-malignant B cells.</p><p id="P33">The association of genetic variants with intratumor maturation states suggests that oncogenic mechanisms are linked to the differentiation process, with specific aberrations potentially more likely to lead to malignancy at different stages of B-cell maturation. Distinct expression patterns of genes with mutations between maturation states support this hypothesis. This could explain why oncogenic mechanisms vary across B-cell lymphoma subtypes. Extending this concept, ongoing differentiation trajectories may promote different survival and proliferation mechanisms within cells of the same tumor. Our recent work with joint single-cell DNA and RNA sequencing of FL and DLBCL validated this, showing that BCL2 variants were enriched in LZ compared to DZ states within the same tumors<sup><xref ref-type="bibr" rid="R56">56</xref></sup>. Characterizing the association between genetic aberrations and tumor maturation states across space and time would provide powerful insights into the relationship between cellular differentiation and clonal evolution.</p><p id="P34">Analogous to variation between organisms drives the evolution of species<sup><xref ref-type="bibr" rid="R68">68</xref></sup>, intratumor heterogeneity drives tumor evolution. We show that the differentiation trajectory of B cells in lymph nodes, B-cell maturation, is a major source of variation in B-cell lymphomas.</p><p id="P35">Intratumor heterogeneity in maturation states blurs subtype boundaries, whereby individual DLBCL and FL tumors can contain multiple clinical subtypes. Gene regulatory networks and cellular interactions central to the B-cell maturation process are predominantly retained in malignancy, while intratumor maturation states occupy distinct spatial microenvironments and may undergo genetic variation. Tumor maturation state profiling revealed subgroups of FL, GCB DLBCL, and ABC DLBCL with striking differences in survival, driven by DZ and IgM memory states. Seeing cellular differentiation as a source of variation in cancer not only illuminates the origins of intratumor heterogeneity, but also sheds light on tumor evolution trajectories and sets the stage for treatment strategies against the emergence of resistant phenotypes.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplemental Data</label><media xlink:href="EMS190788-supplement-Supplemental_Data.pdf" mimetype="application" mime-subtype="pdf" id="d2aAcEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>Supplemental Table 6</label><media xlink:href="EMS190788-supplement-Supplemental_Table_6.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d2aAcEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>Supplemental Table 7</label><media xlink:href="EMS190788-supplement-Supplemental_Table_7.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d2aAcEdB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>Supplemental Table 8</label><media xlink:href="EMS190788-supplement-Supplemental_Table_8.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="d2aAcEeB" position="anchor"/></supplementary-material></sec></body><back><ack id="S15"><title>Acknowledgments</title><p>D.F. was supported by two projects from the German Federal Ministry of Education and Research (SIMONA under grant agreement number 031L0263A and SMART-CARE under grant agreement number 031L0212E), the European Research Council Synergy Grant DECODE under grant agreement No. 810296 and the PhD program of the European Molecular Biology Laboratory (EMBL). T.R. was supported by the German Federal Ministry of Education and Research (SIMONA under grant agreement number 031L0263A) and a physician-scientist fellowship of the Medical Faculty of Heidelberg University. M.A.B. was supported by a Career Development award from the International Myeloma Society (IMS). H.V. was supported by the German Federal Ministry of Education and Research (SIMONA under grant agreement number 031L0263A). N.L. was supported by the Heidelberg School of Oncology (HSO2) fellowship from the National Center for Tumor Diseases Heidelberg. O.W. is supported by an Else-Kröner Excellence Fellowship from the Else-Kröner-Fresenius Stiftung (Project-ID 2021_EKES.13) and the German Research Foundation (DFG, #WE4679/2-1). S.D. was supported by a grant from the Hairy Cell Leukemia Foundation, the Heidelberg Research Centre for Molecular Medicine (HRCMM), and an e:med junior group grant from the German Federal Ministry of Education and Research (BMBF). For the data management, we thank the Scientific Data Storage Heidelberg (SDS@hd) which is funded by the state of Baden-Wurttemberg and a DFG grant (INST 35/1314-1 FUGG). We thank Carolin Kolb (University Hospital Heidelberg), the EMBL Genomics Core Facility (Genecore), and the DKFZ Single-Cell Open Lab (scOpenLab) for their excellent technical assistance. Survival data was provided by the Molecular Mechanisms in Malignant Lymphoma (MMML) Network which received funding from the Deutsche Krebshilfe (DKH). We thank Sarah Kaspar and Felix Schneider at EMBL Data Science Internal Support for providing statistical advice. This manuscript was edited at Life Science Editors.</p></ack><sec id="S16" sec-type="data-availability"><title>Data availability</title><p id="P36">All single-cell sequencing data has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS50000000342. Further information about EGA can be found at <ext-link ext-link-type="uri" xlink:href="https://ega-archive.org/">https://ega-archive.org</ext-link> and "The European Genome-phenome Archive of human data consented for biomedical research". Highly multiplexed immunofluorescence images are available in the <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/bioimage-archive/">EMBL-EBI BioImage Archive</ext-link> under accession ID <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/biostudies/bioimages/studies/S-BIAD1090?key=5a354e1d-021b-41ce-a27b-4890158af743">S-BIAD1090</ext-link>.</p></sec><sec id="S17" sec-type="data-availability"><title>Code availability</title><p id="P37">Code scripts used for data processing, analyses, and figure generation are publicly available at <ext-link ext-link-type="uri" xlink:href="https://github.com/dnfitzgerald/BNHL-atlas">https://github.com/dnfitzgerald/BNHL-atlas</ext-link>.</p></sec><fn-group><fn id="FN2" fn-type="con"><p id="P38"><bold>Author Contributions</bold></p><p id="P39">D.F., W.H., and S.D. conceptualized the project. D.F., T.R., and M.K. performed the single-cell experiments. D.F., T.R., J.M., L.C., P.M.B., and N.L. obtained clinical documentation. D.F., T.R., B.B., J.M., and L.L. performed single-cell data preprocessing and exploratory analyses. A.K. identified B-cell maturation states with flow cytometry and sorted them for RNA sequencing. DF. and B.B. analyzed the RNA sequencing data from sorted maturation states. D.F. characterized malignancy, transcriptional phenotypes, and B-cell maturation states in the CITE-Seq and 5’ BCR data. D.F. performed the maturation gene expression signature scoring. D.F. and A.M. analyzed transcription factor activity. M.A.B. performed the CODEX imaging, with preprocessing by M.A.B., H.V., and E.C. D.F., M.A.B., H.V., A.H., E.C., A.M., and F.C. characterized cell types in the CODEX data. D.F. developed and performed label transfer of B-cell maturation states from the CITE-Seq to CODEX data. A.H. performed cellular neighborhood analysis and characterized neighborhoods with D.F. E.C. and M.M.B. performed cellular interactions likelihood analysis. V.P. analyzed genetic variants in the DNA sequencing data. D.F. inferred and analyzed copy number variation in the single-cell data. R.S. supported the interpretation of the MMML data. W.H. and S.D. acquired most funding and resources. D.F. wrote the original draft which was initially reviewed by M.S., W.H., and S.D. All authors subsequently reviewed the paper.</p></fn><fn id="FN3" fn-type="conflict"><p id="P40"><bold>Disclosure of Conflicts of Interest</bold></p><p id="P41">G.P.N. is a co-founder and stockholder of Akoya Biosciences, Inc. and inventor on patent US9909167 (On-slide staining by primer extension).</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visvader</surname><given-names>JE</given-names></name></person-group><article-title>Cells of origin in cancer</article-title><source>Nature</source><year>2011</year><volume>469</volume><fpage>314</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">21248838</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoadley</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer</article-title><source>Cell</source><year>2018</year><volume>173</volume><fpage>291</fpage><lpage>304</lpage><elocation-id>e6</elocation-id><pub-id pub-id-type="pmcid">PMC5957518</pub-id><pub-id pub-id-type="pmid">29625048</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.022</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>D</given-names></name><name><surname>Tergaonkar</surname><given-names>V</given-names></name></person-group><article-title>Unraveling B cell trajectories at single cell resolution</article-title><source>Trends Immunol</source><year>2022</year><volume>43</volume><fpage>210</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">35090788</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>M</given-names></name><name><surname>Scholtysik</surname><given-names>R</given-names></name><name><surname>Küppers</surname><given-names>R</given-names></name></person-group><chapter-title>Origin and Pathogenesis of B Cell Lymphomas</chapter-title><person-group person-group-type="editor"><name><surname>Küppers</surname><given-names>R</given-names></name></person-group><source>Lymphoma: Methods and Protocols</source><publisher-name>Springer New York</publisher-name><publisher-loc>New York, NY</publisher-loc><year>2019</year><fpage>1</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9151-8_1</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koues</surname><given-names>OI</given-names></name><name><surname>Oltz</surname><given-names>EM</given-names></name><name><surname>Payton</surname><given-names>JE</given-names></name></person-group><article-title>Short-Circuiting Gene Regulatory Networks: Origins of B Cell Lymphoma</article-title><source>Trends Genet</source><year>2015</year><volume>31</volume><fpage>720</fpage><lpage>731</lpage><pub-id pub-id-type="pmcid">PMC4674374</pub-id><pub-id pub-id-type="pmid">26604030</pub-id><pub-id pub-id-type="doi">10.1016/j.tig.2015.09.006</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahler</surname><given-names>DW</given-names></name><name><surname>Pindzola</surname><given-names>JA</given-names></name><name><surname>Swerdlow</surname><given-names>SH</given-names></name></person-group><article-title>Splenic marginal zone lymphomas appear to originate from different B cell types</article-title><source>Am J Pathol</source><year>2002</year><volume>161</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="pmcid">PMC1850701</pub-id><pub-id pub-id-type="pmid">12107092</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9440(10)64159-4</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Küppers</surname><given-names>R</given-names></name></person-group><article-title>Mechanisms of B-cell lymphoma pathogenesis</article-title><source>Nat Rev Cancer</source><year>2005</year><volume>5</volume><fpage>251</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">15803153</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shankland</surname><given-names>KR</given-names></name><name><surname>Armitage</surname><given-names>JO</given-names></name><name><surname>Hancock</surname><given-names>BW</given-names></name></person-group><article-title>Non-Hodgkin lymphoma</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>848</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">22835603</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome</article-title><source>J Exp Med</source><year>2020</year><volume>217</volume><pub-id pub-id-type="pmcid">PMC7537389</pub-id><pub-id pub-id-type="pmid">32603407</pub-id><pub-id pub-id-type="doi">10.1084/jem.20200483</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roider</surname><given-names>T</given-names></name><etal/></person-group><article-title>Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels</article-title><source>Nat Cell Biol</source><year>2020</year><volume>22</volume><fpage>896</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">32541878</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayers</surname><given-names>EC</given-names></name><etal/></person-group><article-title>Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure</article-title><source>Cancer</source><year>2020</year><volume>126</volume><fpage>293</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">31568564</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study</article-title><source>J Leukoc Biol</source><year>2022</year><pub-id pub-id-type="pmid">36040107</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerlinger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Intratumor heterogeneity and branched evolution revealed by multiregion sequencing</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><fpage>883</fpage><lpage>892</lpage><pub-id pub-id-type="pmcid">PMC4878653</pub-id><pub-id pub-id-type="pmid">22397650</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa1113205</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGranahan</surname><given-names>N</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name></person-group><article-title>Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>613</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">28187284</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><elocation-id>596493</elocation-id><pub-id pub-id-type="pmcid">PMC7747763</pub-id><pub-id pub-id-type="pmid">33344244</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2020.596493</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turajlic</surname><given-names>S</given-names></name><etal/></person-group><article-title>Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal</article-title><source>Cell</source><year>2018</year><volume>173</volume><fpage>595</fpage><lpage>610</lpage><elocation-id>e11</elocation-id><pub-id pub-id-type="pmcid">PMC5938372</pub-id><pub-id pub-id-type="pmid">29656894</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.043</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Subclonal diversification of primary breast cancer revealed by multiregion sequencing</article-title><source>Nat Med</source><year>2015</year><volume>21</volume><fpage>751</fpage><lpage>759</lpage><pub-id pub-id-type="pmcid">PMC4500826</pub-id><pub-id pub-id-type="pmid">26099045</pub-id><pub-id pub-id-type="doi">10.1038/nm.3886</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sangaletti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces</article-title><source>EBioMedicine</source><year>2020</year><volume>61</volume><elocation-id>103055</elocation-id><pub-id pub-id-type="pmcid">PMC7581880</pub-id><pub-id pub-id-type="pmid">33096480</pub-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.103055</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roider</surname><given-names>T</given-names></name><etal/></person-group><article-title>Multimodal and spatially resolved profiling identifies distinct patterns of T-cell infiltration in nodal B-cell lymphoma entities</article-title><source>bioRxiv</source><year>2022</year><elocation-id>2022.11.04.514366</elocation-id><pub-id pub-id-type="pmcid">PMC10940160</pub-id><pub-id pub-id-type="pmid">38379051</pub-id><pub-id pub-id-type="doi">10.1038/s41556-024-01358-2</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batlle</surname><given-names>E</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Cancer stem cells revisited</article-title><source>Nat Med</source><year>2017</year><volume>23</volume><fpage>1124</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">28985214</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez-González</surname><given-names>A</given-names></name><name><surname>Bévant</surname><given-names>K</given-names></name><name><surname>Blanpain</surname><given-names>C</given-names></name></person-group><article-title>Cancer cell plasticity during tumor progression, metastasis and response to therapy</article-title><source>Nat Cancer</source><year>2023</year><pub-id pub-id-type="pmcid">PMC7615147</pub-id><pub-id pub-id-type="pmid">37537300</pub-id><pub-id pub-id-type="doi">10.1038/s43018-023-00595-y</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milpied</surname><given-names>P</given-names></name><etal/></person-group><article-title>Human germinal center transcriptional programs are de-synchronized in B cell lymphoma</article-title><source>Nat Immunol</source><year>2018</year><volume>19</volume><fpage>1013</fpage><lpage>1024</lpage><pub-id pub-id-type="pmid">30104629</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steen</surname><given-names>CB</given-names></name><etal/></person-group><article-title>The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><fpage>1422</fpage><lpage>1437</lpage><elocation-id>e10</elocation-id><pub-id pub-id-type="pmcid">PMC9205168</pub-id><pub-id pub-id-type="pmid">34597589</pub-id><pub-id pub-id-type="doi">10.1016/j.ccell.2021.08.011</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Alberts</surname><given-names>B</given-names></name><etal/></person-group><source>Molecular Biology of the Cell</source><publisher-name>Garland Science</publisher-name><year>2014</year></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruijtenberg</surname><given-names>S</given-names></name><name><surname>van den Heuvel</surname><given-names>S</given-names></name></person-group><article-title>Coordinating cell proliferation and differentiation: Antagonism between cell cycle regulators and cell type-specific gene expression</article-title><source>Cell Cycle</source><year>2016</year><volume>15</volume><fpage>196</fpage><lpage>212</lpage><pub-id pub-id-type="pmcid">PMC4825819</pub-id><pub-id pub-id-type="pmid">26825227</pub-id><pub-id pub-id-type="doi">10.1080/15384101.2015.1120925</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><article-title>Hallmarks of cancer: New dimensions</article-title><source>Cancer Discov</source><year>2022</year><volume>12</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">35022204</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roider</surname><given-names>T</given-names></name><name><surname>Brinkmann</surname><given-names>BJ</given-names></name><name><surname>Dietrich</surname><given-names>S</given-names></name></person-group><article-title>Processing human lymph node samples for single-cell assays</article-title><source>STAR Protoc</source><year>2021</year><volume>2</volume><elocation-id>100914</elocation-id><pub-id pub-id-type="pmcid">PMC8551229</pub-id><pub-id pub-id-type="pmid">34746869</pub-id><pub-id pub-id-type="doi">10.1016/j.xpro.2021.100914</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoeckius</surname><given-names>M</given-names></name><etal/></person-group><article-title>Simultaneous epitope and transcriptome measurement in single cells</article-title><source>Nat Methods</source><year>2017</year><volume>14</volume><fpage>865</fpage><lpage>868</lpage><pub-id pub-id-type="pmcid">PMC5669064</pub-id><pub-id pub-id-type="pmid">28759029</pub-id><pub-id pub-id-type="doi">10.1038/nmeth.4380</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Integrated analysis of multimodal single-cell data</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>3573</fpage><lpage>3587</lpage><elocation-id>e29</elocation-id><pub-id pub-id-type="pmcid">PMC8238499</pub-id><pub-id pub-id-type="pmid">34062119</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2021.04.048</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>S</given-names></name><etal/></person-group><article-title>CODEX multiplexed tissue imaging with DNA-conjugated antibodies</article-title><source>Nat Protoc</source><year>2021</year><volume>16</volume><fpage>3802</fpage><lpage>3835</lpage><pub-id pub-id-type="pmcid">PMC8647621</pub-id><pub-id pub-id-type="pmid">34215862</pub-id><pub-id pub-id-type="doi">10.1038/s41596-021-00556-8</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aibar</surname><given-names>S</given-names></name><etal/></person-group><article-title>SCENIC: single-cell regulatory network inference and clustering</article-title><source>Nat Methods</source><year>2017</year><volume>14</volume><fpage>1083</fpage><lpage>1086</lpage><pub-id pub-id-type="pmcid">PMC5937676</pub-id><pub-id pub-id-type="pmid">28991892</pub-id><pub-id pub-id-type="doi">10.1038/nmeth.4463</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R</given-names></name><etal/></person-group><article-title>Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes</article-title><source>Nat Biotechnol</source><year>2021</year><volume>39</volume><fpage>599</fpage><lpage>608</lpage><pub-id pub-id-type="pmcid">PMC8122019</pub-id><pub-id pub-id-type="pmid">33462507</pub-id><pub-id pub-id-type="doi">10.1038/s41587-020-00795-2</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korotkevich</surname><given-names>G</given-names></name><etal/></person-group><article-title>Fast gene set enrichment analysis</article-title><source>bioRxiv</source><year>2021</year><elocation-id>060012</elocation-id><pub-id pub-id-type="doi">10.1101/060012</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title><source>Cell Syst</source><year>2015</year><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="pmcid">PMC4707969</pub-id><pub-id pub-id-type="pmid">26771021</pub-id><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeffler-Wirth</surname><given-names>H</given-names></name><etal/></person-group><article-title>A modular transcriptome map of mature B cell lymphomas</article-title><source>Genome Med</source><year>2019</year><volume>11</volume><fpage>27</fpage><pub-id pub-id-type="pmcid">PMC6492344</pub-id><pub-id pub-id-type="pmid">31039827</pub-id><pub-id pub-id-type="doi">10.1186/s13073-019-0637-7</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Determining cell type abundance and expression from bulk tissues with digital cytometry</article-title><source>Nat Biotechnol</source><year>2019</year><volume>37</volume><fpage>773</fpage><lpage>782</lpage><pub-id pub-id-type="pmcid">PMC6610714</pub-id><pub-id pub-id-type="pmid">31061481</pub-id><pub-id pub-id-type="doi">10.1038/s41587-019-0114-2</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Therneau</surname><given-names>TM</given-names></name><name><surname>Grambsch</surname><given-names>PM</given-names></name></person-group><source>Modeling Survival Data: Extending the Cox Model</source><publisher-name>Springer Science &amp; Business Media</publisher-name><year>2013</year></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Kassambara</surname><given-names>A</given-names></name><name><surname>Kosinski</surname><given-names>M</given-names></name><name><surname>Biecek</surname><given-names>P</given-names></name><name><surname>Fabian</surname><given-names>S</given-names></name></person-group><source>survminer: Drawing Survival Curves using ‘ggplot2’ 2019 R package version 0. 4</source><year>2021</year><volume>4</volume></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laidlaw</surname><given-names>BJ</given-names></name><name><surname>Duan</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Vazquez</surname><given-names>SE</given-names></name><name><surname>Cyster</surname><given-names>JG</given-names></name></person-group><article-title>The transcription factor Hhex cooperates with the corepressor Tle3 to promote memory B cell development</article-title><source>Nat Immunol</source><year>2020</year><volume>21</volume><fpage>1082</fpage><lpage>1093</lpage><pub-id pub-id-type="pmcid">PMC7442689</pub-id><pub-id pub-id-type="pmid">32601467</pub-id><pub-id pub-id-type="doi">10.1038/s41590-020-0713-6</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidwell</surname><given-names>T</given-names></name><name><surname>Kallies</surname><given-names>A</given-names></name></person-group><article-title>Bach2 is required for B cell and T cell memory differentiation</article-title><source>Nat Immunol</source><year>2016</year><volume>17</volume><fpage>744</fpage><lpage>745</lpage><pub-id pub-id-type="pmid">27327995</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattoretti</surname><given-names>G</given-names></name><etal/></person-group><article-title>Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>3967</fpage><lpage>3975</lpage><pub-id pub-id-type="pmid">16439679</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goteri</surname><given-names>G</given-names></name><etal/></person-group><article-title>Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas</article-title><source>Diagn Pathol</source><year>2011</year><volume>6</volume><fpage>97</fpage><pub-id pub-id-type="pmcid">PMC3201901</pub-id><pub-id pub-id-type="pmid">21988858</pub-id><pub-id pub-id-type="doi">10.1186/1746-1596-6-97</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delia</surname><given-names>D</given-names></name><etal/></person-group><article-title>CD1c but neither CD1a nor CD1b molecules are expressed on normal, activated, and malignant human B cells: identification of a new B-cell subset</article-title><source>Blood</source><year>1988</year><volume>72</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">3260523</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ratech</surname><given-names>H</given-names></name><name><surname>Litwin</surname><given-names>S</given-names></name></person-group><article-title>Surface immunoglobulin light chain restriction in B-cell non-Hodgkin’s malignant lymphomas</article-title><source>Am J Clin Pathol</source><year>1989</year><volume>91</volume><fpage>583</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">2497637</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuart</surname><given-names>T</given-names></name><etal/></person-group><article-title>Comprehensive Integration of Single-Cell Data</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>1888</fpage><lpage>1902</lpage><elocation-id>e21</elocation-id><pub-id pub-id-type="pmcid">PMC6687398</pub-id><pub-id pub-id-type="pmid">31178118</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.031</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khodabakhshi</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Recurrent targets of aberrant somatic hypermutation in lymphoma</article-title><source>Oncotarget</source><year>2012</year><volume>3</volume><fpage>1308</fpage><lpage>1319</lpage><pub-id pub-id-type="pmcid">PMC3717795</pub-id><pub-id pub-id-type="pmid">23131835</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.653</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argelaguet</surname><given-names>R</given-names></name><etal/></person-group><article-title>Multi-Omics Factor Analysis-a framework for unsupervised integration of multi-omics data sets</article-title><source>Mol Syst Biol</source><year>2018</year><volume>14</volume><elocation-id>e8124</elocation-id><pub-id pub-id-type="pmcid">PMC6010767</pub-id><pub-id pub-id-type="pmid">29925568</pub-id><pub-id pub-id-type="doi">10.15252/msb.20178124</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohanty</surname><given-names>A</given-names></name><etal/></person-group><article-title>CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>73558</fpage><lpage>73572</lpage><pub-id pub-id-type="pmcid">PMC5341999</pub-id><pub-id pub-id-type="pmid">27713153</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.12434</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue</article-title><source>Blood</source><year>2014</year><volume>123</volume><fpage>1214</fpage><lpage>1217</lpage><pub-id pub-id-type="pmcid">PMC3931191</pub-id><pub-id pub-id-type="pmid">24398326</pub-id><pub-id pub-id-type="doi">10.1182/blood-2013-11-536433</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>PN</given-names></name><etal/></person-group><article-title>Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>200</fpage><lpage>207</lpage><pub-id pub-id-type="pmcid">PMC3058275</pub-id><pub-id pub-id-type="pmid">21135273</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2010.30.0368</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>Y-K</given-names></name><name><surname>Jang</surname><given-names>E</given-names></name><name><surname>Paik</surname><given-names>D-J</given-names></name><name><surname>Youn</surname><given-names>J</given-names></name></person-group><article-title>Early Growth Response-1 Plays a Non-redundant Role in the Differentiation of B Cells into Plasma Cells</article-title><source>Immune Netw</source><year>2015</year><volume>15</volume><fpage>161</fpage><lpage>166</lpage><pub-id pub-id-type="pmcid">PMC4486779</pub-id><pub-id pub-id-type="pmid">26140048</pub-id><pub-id pub-id-type="doi">10.4110/in.2015.15.3.161</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagman</surname><given-names>J</given-names></name><name><surname>Lukin</surname><given-names>K</given-names></name></person-group><article-title>Transcription factors drive B cell development</article-title><source>Curr Opin Immunol</source><year>2006</year><volume>18</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">16464566</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basso</surname><given-names>K</given-names></name><name><surname>Dalla-Favera</surname><given-names>R</given-names></name></person-group><article-title>Germinal centres and B cell lymphomagenesis</article-title><source>Nat Rev Immunol</source><year>2006</year><volume>18</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">25712152</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaffer</surname><given-names>AL</given-names><suffix>3rd</suffix></name><name><surname>Young</surname><given-names>RM</given-names></name><name><surname>Staudt</surname><given-names>LM</given-names></name></person-group><article-title>Pathogenesis of human B cell lymphomas</article-title><source>Annu Rev Immunol</source><year>2012</year><volume>30</volume><fpage>565</fpage><lpage>610</lpage><pub-id pub-id-type="pmcid">PMC7478144</pub-id><pub-id pub-id-type="pmid">22224767</pub-id><pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-075027</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>F</given-names></name><etal/></person-group><article-title>Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma</article-title><source>Br J Haematol</source><year>2023</year><pub-id pub-id-type="pmid">37455019</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindenhofer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Functional phenotyping of genomic variants using multiomic scDNA-scRNA-seq</article-title><source>bioRxiv</source><year>2024</year><elocation-id>2024.05.31.596895</elocation-id><pub-id pub-id-type="doi">10.1101/2024.05.31.596895</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitz</surname><given-names>R</given-names></name><etal/></person-group><article-title>Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics</article-title><source>Nature</source><year>2012</year><volume>490</volume><fpage>116</fpage><lpage>120</lpage><pub-id pub-id-type="pmcid">PMC3609867</pub-id><pub-id pub-id-type="pmid">22885699</pub-id><pub-id pub-id-type="doi">10.1038/nature11378</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Draetta</surname><given-names>GF</given-names></name></person-group><article-title>Tumors and mitochondrial respiration: a neglected connection</article-title><source>Cancer Res</source><year>2015</year><volume>75</volume><fpage>3685</fpage><lpage>3686</lpage><pub-id pub-id-type="pmid">26374463</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>M</given-names></name><etal/></person-group><article-title>Functional capacities of human IgM memory B cells in early inflammatory responses and secondary germinal center reactions</article-title><source>Proc Natl Acad Sci U S A</source><year>2015</year><volume>112</volume><fpage>E546</fpage><lpage>55</lpage><pub-id pub-id-type="pmcid">PMC4330750</pub-id><pub-id pub-id-type="pmid">25624468</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1416276112</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapuy</surname><given-names>B</given-names></name><etal/></person-group><article-title>Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes</article-title><source>Nat Med</source><year>2018</year><volume>24</volume><fpage>679</fpage><lpage>690</lpage><pub-id pub-id-type="pmcid">PMC6613387</pub-id><pub-id pub-id-type="pmid">29713087</pub-id><pub-id pub-id-type="doi">10.1038/s41591-018-0016-8</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alduaij</surname><given-names>W</given-names></name><etal/></person-group><article-title>Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population</article-title><source>Blood</source><year>2023</year><volume>141</volume><fpage>2493</fpage><lpage>2507</lpage><pub-id pub-id-type="pmid">36302166</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>GW</given-names></name><etal/></person-group><article-title>A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications</article-title><source>Cancer Cell</source><year>2020</year><volume>37</volume><fpage>551</fpage><lpage>568</lpage><elocation-id>e14</elocation-id><pub-id pub-id-type="pmcid">PMC8459709</pub-id><pub-id pub-id-type="pmid">32289277</pub-id><pub-id pub-id-type="doi">10.1016/j.ccell.2020.03.015</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="web"><source>Pharos: Illuminating the Druggable Genome</source><comment><ext-link ext-link-type="uri" xlink:href="https://pharos.nih.gov/">https://pharos.nih.gov/</ext-link></comment></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>DW</given-names></name><name><surname>Gascoyne</surname><given-names>RD</given-names></name></person-group><article-title>The tumour microenvironment in B cell lymphomas</article-title><source>Nat Rev Cancer</source><year>2014</year><volume>14</volume><fpage>517</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">25008267</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>MP</given-names></name><name><surname>Pittaluga</surname><given-names>S</given-names></name><name><surname>Jaffe</surname><given-names>ES</given-names></name></person-group><article-title>The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification</article-title><source>Cancer J</source><year>2012</year><volume>18</volume><fpage>411</fpage><lpage>420</lpage><pub-id pub-id-type="pmcid">PMC3458515</pub-id><pub-id pub-id-type="pmid">23006945</pub-id><pub-id pub-id-type="doi">10.1097/PPO.0b013e31826aee97</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma</article-title><source>Blood</source><year>2019</year><volume>134</volume><fpage>4077</fpage><pub-id pub-id-type="pmid">35503708</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sermer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies</article-title><source>Blood Adv</source><year>2020</year><volume>4</volume><fpage>4669</fpage><lpage>4678</lpage><pub-id pub-id-type="pmcid">PMC7556134</pub-id><pub-id pub-id-type="pmid">33002134</pub-id><pub-id pub-id-type="doi">10.1182/bloodadvances.2020002118</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Darwin</surname><given-names>C</given-names></name></person-group><source>On the Origin of Species by Means of Natural Selection, Or, the Preservation of Favoured Races in the Struggle for Life</source><publisher-name>MVB E-Books</publisher-name><year>2010</year><pub-id pub-id-type="pmcid">PMC5184128</pub-id><pub-id pub-id-type="pmid">30164232</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="other"><collab>BioRender</collab><source>Created with BioRender com</source><year>2021</year><comment>Preprint at</comment></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>DR</given-names></name></person-group><article-title>The Regression Analysis of Binary Sequences</article-title><source>J R Stat Soc Series B Stat Methodol</source><year>1958</year><volume>20</volume><fpage>215</fpage><lpage>242</lpage></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Woolson</surname><given-names>RF</given-names></name></person-group><source>Wilcoxon Signed-Rank Test</source><publisher-name>Wiley Encyclopedia of Clinical Trials</publisher-name><year>2008</year><pub-id pub-id-type="doi">10.1002/9780471462422.eoct979</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finak</surname><given-names>G</given-names></name><etal/></person-group><article-title>MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data</article-title><source>Genome Biol</source><year>2015</year><volume>16</volume><fpage>278</fpage><pub-id pub-id-type="pmcid">PMC4676162</pub-id><pub-id pub-id-type="pmid">26653891</pub-id><pub-id pub-id-type="doi">10.1186/s13059-015-0844-5</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing</article-title><source>J R Stat Soc Series B Stat Methodol</source><year>1995</year><volume>57</volume><fpage>289</fpage><lpage>300</lpage></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Key Points</title></caption><list list-type="bullet" id="L1"><list-item><p>Cellular differentiation remains plastic in B-cell lymphomas, driving tumor variation, evolution, and response.</p></list-item><list-item><p>Intratumor maturation states occupy unique immune niches, harbor distinct genetic variants, and are tied to different survival outcomes.</p></list-item></list></boxed-text><fig id="F1" position="float"><label>Fig. 1</label><caption><title>A single-cell B-cell maturation reference map in reactive lymph nodes</title><p><bold>a</bold>, Schematic of the B-cell maturation trajectory in the lymph node. The labeled populations represent the B-cell maturation states characterized by FACS and CITE-Seq. Illustrations were created with BioRender.com<sup><xref ref-type="bibr" rid="R69">69</xref></sup>. <bold>b</bold>, Transcriptomic UMAP of the rLN reference CITE-Seq dataset (8 samples) labeled by the B-cell maturation states in a. Transcriptomic clusters were assigned to maturation states based on their expression of the maturation markers in <xref ref-type="supplementary-material" rid="SD1">Supplemental Table 5</xref>. <bold>c</bold>, Heatmap showing the z-scored average expression of a subset of markers for each maturation state annotated in the reference CITE-Seq dataset. <bold>d</bold>, Confusion matrix of cells’ maturation state labels annotated by maturation marker profiling of transcriptomic clusters (y-axis) and predicted by a logistic regression<sup><xref ref-type="bibr" rid="R70">70</xref></sup> classifier trained on RNA-sequencing data from B-cell maturation states sorted with FACS (x-axis) (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 1</xref>). The color scale shows probability estimates for each class. Maturation state annotations: Naïve = Naïve B cells, DZ = Centroblasts from the dark zone of the germinal center, LZ = Centrocytes from the light zone of the germinal center, Mem IgM = IgD+ and IgM+ memory B cells, Mem IgG = class-switched (IgG+ or IgA+) memory B cells, Plasma = plasma cells.</p></caption><graphic xlink:href="EMS190788-f001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><title>Tumors consist of multiple B-cell maturation states</title><p><bold>a</bold>, Transcriptomic UMAPs for individual samples from each subtype, labeled by B-cell maturation states assigned by label transfer from the reactive lymph node reference (<xref ref-type="fig" rid="F1">Fig. 1b</xref>). Only malignant cells are shown for tumor samples. <bold>b</bold>, Maturation state composition of all samples (n=51) split by subtype and ordered by days since diagnosis. <bold>c</bold>, Box plot of the proportion of each maturation state in each subtype. Each data point is a sample, grouped by subtype. The Wilcoxon signed-rank test<sup><xref ref-type="bibr" rid="R71">71</xref></sup> (two-sided) was performed for each maturation state’s proportion between reactive lymph nodes and each subtype: p&lt;0.05 (*), p&lt;0.01 (**), p&lt;0.001 (***). Centerline = median, box limits = upper and lower quartiles, whiskers = 1.5x interquartile range. rLN = reactive lymph nodes, MCL = mantle cell lymphoma, FL = follicular lymphoma, DLBCL = diffuse large B-cell lymphoma (GCB = germinal center, non-GCB/ABC = activated B cell), MZL = marginal zone lymphoma. See <xref ref-type="fig" rid="F1">Fig. 1</xref> for maturation state annotations.</p></caption><graphic xlink:href="EMS190788-f002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><title>Cell-of-origin classification reveals multiple subtypes within each tumor</title><p><bold>a</bold>, Normalized GCB and ABC scores for each DLBCL and FL tumor cell determined by the Lymph2Cx cell-of-origin classifier, labeled by B-cell maturation state. The diagonal line divides cells by their classification (above = ABC, below = GCB). Cells without ABC or GCB gene set average expression above the housekeeping genes were unclassified (grey box). <bold>b-c</bold>, Lymph2Cx class proportions among the tumor cells of DLBCL samples faceted by GCB or non-GCB diagnosis (b) and FL samples (c). <bold>d</bold>, Normalized GCB and ABC scores for each DLBCL and FL tumor cell determined by the Lymph2Cx classifier, as shown in (a), labeled by Tally class. <bold>e-f</bold>, Tally class proportions among the tumor cells of DLBCL samples faceted by GCB or non-GCB diagnosis (e) and FL samples (f). FL = follicular lymphoma, DLBCL = diffuse large B-cell lymphoma (GCB = germinal center, non-GCB = non-germinal center), COO = cell of origin. See <xref ref-type="fig" rid="F1">Fig.1</xref> for maturation state annotations.</p></caption><graphic xlink:href="EMS190788-f003"/></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><title>Maturation signature TFs maintain differential activity in malignancy</title><p><bold>a</bold>, Scaled activity of transcription factors (TFs) across B-cell maturation states in each subtype inferred using the <italic>scenic</italic> python package<sup><xref ref-type="bibr" rid="R31">31</xref></sup>; only TFs significantly enriched (log2 fold-change &gt;0.4, p &lt; 10e-16 as determined with the <italic>MAST</italic> R package<sup><xref ref-type="bibr" rid="R72">72</xref></sup>) for B-cell maturation stages target genes in reactive lymph node samples are shown. TFs (y-axis) are ordered by the maturation state in reactive lymph nodes in which they are enriched. Non-malignant cells in tumor samples were excluded based on light-chain restriction. <bold>b</bold>, Density plots comparing the activity distribution of a subset of distinguishing transcription factors in each tumor maturation state in malignant cells aggregated from all tumor samples (n = 43). rLN = reactive lymph node, MCL = mantle cell lymphoma, FL = follicular lymphoma, DLBCL = diffuse large B-cell lymphoma (GCB = germinal center, non-GCB = non-germinal center), MZL = marginal zone lymphoma. See <xref ref-type="fig" rid="F1">Fig. 1</xref> for maturation state annotations.</p></caption><graphic xlink:href="EMS190788-f004"/></fig><fig id="F5" position="float"><label>Fig. 5</label><caption><title>Maturation states occupy distinct tumor microenvironments</title><p><bold>a</bold>, UMAP of scRNA-seq data labeled by B-cell maturation states mapped from the reactive lymph node reference with B-cell maturation state proportions (top), and spatial distribution of B-cell maturation states in a reactive lymph node (rLN), follicular (FL), mantle cell (MCL), and non-germinal center diffuse large B-cell lymphoma (DLBCL, non-GCB) sample from CODEX<sup><xref ref-type="bibr" rid="R30">30</xref></sup> images (52 markers) on FFPE tissue sections (bottom). See <xref ref-type="supplementary-material" rid="SD1">Supplemental Fig. 9</xref> for the distribution of maturation states and cell types on all CODEX slides (n=29). <bold>b</bold>, Log<sub>2</sub> of the pairwise cell-cell observed over expected interaction ratios (IR) between B-cell maturation states and all other cell types in each subtype, with a pseudocount of 1. Spatial interactions were determined with Delaunay triangulation. A higher ratio is associated with increased proximity. B Naïve = naïve B cells, B DZ = centroblasts from the dark zone of the germinal center, B LZ = centrocytes from the light zone of the germinal center, B Mem IgM = IgD+ and IgM+ memory B cells, B Mem IgG = class-switched (IgG+ or IgA+) memory B cells, B Plasma = plasma cells, CD4T_naive = naive CD4+ T-cells, CD8T_naive = naive CD8+ T-cells, TH_memory = memory helper T-cells, TTOX_memory = memory cytotoxic T-cells, TTOX_exh = exhausted cytotoxic T-cells, NKT = natural killer T-cells, TFH = follicular helper T-cells, TPR = proliferating T-cells, TREG = regulatory T-cells, FDC = follicular dendritic cells, DC = dendritic cells, Macro = macrophages, Stromal = stromal cells, NK = natural killer cells, MC = monocytes, Granulo = granulocytes.</p></caption><graphic xlink:href="EMS190788-f005"/></fig><fig id="F6" position="float"><label>Fig. 6</label><caption><title>Genetic variants among intratumor maturation states</title><p><bold>a-c</bold>, Reference-based UMAP of malignant cells from FL7 labeled by (a) B-cell maturation state, (b) diploid or aneuploid status, and (c) copy number variation (CNV) in chromosomal position 6-26329011 (cytogenetic band 6p22.2) among tumor cells. CNV was inferred from gene expression with the <italic>copykat</italic> R package<sup><xref ref-type="bibr" rid="R32">32</xref></sup>. <bold>d</bold>, Frequencies of the aneuploid and diploid variants in each intratumor maturation state in FL7. <bold>e</bold>, The average expression (z-scaled) and percentage of cells expressing genes with non-silent mutations detected with targeted DNA sequencing (<xref ref-type="supplementary-material" rid="SD1">Supplemental Fig.11</xref>) in samples from mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and marginal zone lymphoma (MZL). See <xref ref-type="fig" rid="F1">Fig. 1</xref> for maturation state annotations.</p></caption><graphic xlink:href="EMS190788-f006"/></fig><fig id="F7" position="float"><label>Fig. 7</label><caption><title>Tumor maturation state composition predicts survival</title><p><bold>a</bold>, Hazard ratios for each maturation state (for 1 standard deviation) across tumors and their 95% confidence intervals are shown with respect to overall survival from 507 tumors (119 DLBCL GCB, 102 DLBCL ABC, 79 unclassified DLBCL, 44 double-hit DLBCL, 94 BCL2-break positive FL, 25 BCL2-break negative FL, 2 BCL-break unknown FL, and 42 mixed FL/DLBCL (FL grade 3B)). Significant hazard ratios (adjusted p&lt;0.05, Log-Rank test, Benjamini-Hochberg adjusted<sup><xref ref-type="bibr" rid="R73">73</xref></sup>) are shown in red. See <xref ref-type="fig" rid="F1">Fig. 1</xref> for B-cell maturation state annotations. <bold>d-f</bold>, Kaplan-Meier curves are shown for <bold>d</bold>, DZ high and low (&gt;/&lt; 1.9%) subgroups of FL, <bold>e</bold>, IgM memory high and low (&gt;/&lt; 2.66%) subgroups of DLBCL GCB, <bold>f</bold>, IgM memory high and low (&gt;/&lt; 1.4%) subgroups of DLBCL ABC. P-values were determined with the log-rank test and 95% confidence intervals are shown.</p></caption><graphic xlink:href="EMS190788-f007"/></fig></floats-group></article>